New studies, international collaboration and the involvement of those affected: the SPOG Annual Report 2025 highlights the impact of research on children and young people with cancer in Switzerland and shows the people who make it possible.
At the end of 2025, 14 clinical trials and 14 research projects for children and young people with cancer were open. A new clinical trial on acute myeloid leukaemia (CHIP-AML22/Master) was opened, as well as two research projects on acute lymphoblastic leukaemia and soft tissue tumours.
The people behind the studies
A key feature of the annual report is the interview with PD Dr Nicolas Gerber, Senior Consultant at the University Children’s Hospital Zurich and Vice-President of SPOG. As national study coordinator, he provides insight into his work and explains how international paediatric cancer studies are coordinated and implemented in Switzerland.
Another milestone in 2025 was the establishment of the SPOG Patient Advisory Board (SPAB). The new Patient Advisory Board brings the perspectives of survivors and affected parents directly into SPOG’s research and activities.
Many thanks for your support
SPOG’s work is only possible thanks to the support of numerous partners. We would like to sincerely thank the Swiss Confederation, our foundations, companies and private donors for their trust and support.
Take a look at the new Annual Report:
Annual Report 2025
Audit Report 2025
Please note: The Annual Report is available in German, French, Italian and English. The Audit Report is available in German only.
Gina Eggenschwiler
Gina Eggenschwiler is responsible for communications at SPOG and has a wealth of experience in marketing. She specialises in communication campaigns.
More articles from Gina Eggenschwiler 
